Insider Buying: Tharimmune, Inc. (NASDAQ:THAR) COO Acquires $10,100.00 in Stock

Tharimmune, Inc. (NASDAQ:THAR) COO Sireesh Appajosyula purchased 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The stock was bought at an average price of $2.02 per share, for a total transaction of $10,100.00. Following the purchase, the chief operating officer now owns 10,758 shares in the company, valued at $21,731.16. The trade was a 86.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

Sireesh Appajosyula also recently made the following trade(s):

• On Tuesday, October 8th, Sireesh Appajosyula acquired 5,000 shares of Tharimmune stock. The shares were purchased at an average price of $1.93 per share, with a total value of $9,650.00.

Tharimmune Trading Down 2.7 %

Shares of NASDAQ THAR opened at $2.17 on Friday. The business’s 50 day moving average is $2.44 and its 200-day moving average is $3.35. Tharimmune, Inc. has a 1-year low of $1.84 and a 1-year high of $79.65.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tharimmune stock. Curi RMB Capital LLC bought a new stake in Tharimmune, Inc. (NASDAQ:THAR) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned 2.06% of Tharimmune as of its most recent filing with the Securities and Exchange Commission (SEC). 1.16% of the stock is owned by institutional investors and hedge funds.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).